Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI 287 in Recurrent or Progressed Glioblastoma Multiforme
NCT01113463Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abeotaxane in glioblastoma multiforme (GBM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival at 6 months. Started Apr 2010; status: terminated.
02
Drugs
abeotaxane
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01113463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01113463.